Over the last 25 years, hundreds of clinical trials for drugs treating Alzheimer’s disease have failed. As the field takes stock, a team at IU School of Medicine hunts for new targets—and hope for patients.
COMBING THE SCIENTIFIC literature, Tim Corson, PhD, searched for a new way to treat macular degeneration, the deterioration of part of the retina. It led to him to an unlikely place. A delicate orchid. Or more accurately, a medicinal compound the orchid produces. Patients diagnosed with wet age-related macular degeneration spend their golden years in a gauzy haze. Inside their eye, abnormal blood vessels sprout underneath tissue in the center of the retina. These vessels leak fluid, creating scar tissue. […]
XIONGBIN LU, PhD, spends his days engrossed in research into the factors that lead normal breast tissue cells to turn into Triple Negative Breast Cancer—and engineering therapies to stop it. Across the hall from Lu’s lab, Xinna Zhang, PhD, dives deeply into her the study of the biology of HER2-positive breast cancer, and what makes cells resistant to drug therapies. But Lu and Zhang share more than their proximity to one another in the Vera Bradley Foundation Breast Cancer Research […]
Because of a revolutionary therapy developed by Dr. Larry Einhorn and his colleagues at IU School of Medicine, James Mikesh is part of a legion of survivors of a disease that once killed 95 percent of patients. Now, 95 percent of patients are cured.